{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:44:35Z","timestamp":1793684675786,"version":"4.5.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacc.2026.07.015","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:32:06Z","timestamp":1788161526000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-6464","authenticated-orcid":false,"given":"Steven E.","family":"Nissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"St. John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacc.2026.07.015_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacc.2026.07.015_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacc.2026.07.015_bib3","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2013.12.030","article-title":"Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a)","volume":"63","author":"Tsimikas","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2026.07.015_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13710","article-title":"Oxidized phospholipids and lipoprotein(a): an update","volume":"52","author":"Koutsogianni","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"18","key":"10.1016\/j.jacc.2026.07.015_bib5","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","article-title":"Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes","volume":"81","author":"Gilliland","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacc.2026.07.015_bib6","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2024.08.070","article-title":"Oxidized phospholipids and calcific aortic valvular disease","volume":"84","author":"Bhatia","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.07.015_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacc.2026.07.015_bib8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacc.2026.07.015_bib9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.jacc.2026.07.015_bib10","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jacc.2026.07.015_bib11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2026.07.015_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jacc.2026.07.015_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2026.100976","article-title":"Analytical validation of monoclonal antibody-based ELISA methods for OxPL-apoB and OxPL-apo(a)","volume":"67","author":"Marcovina","year":"2026","journal-title":"J Lipid Res"},{"issue":"13","key":"10.1016\/j.jacc.2026.07.015_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial","volume":"65","author":"Byun","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2026.07.015_bib15","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacc.2026.07.015_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamacardio.2024.5433","article-title":"Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers: results from the OCEAN(a)-DOSE trial","volume":"10","author":"Rosenson","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2026.07.015_bib17","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/ATVBAHA.125.322347","article-title":"Oxidized phospholipids on apoB-100, platelet activation and reactivity, and long-term cardiovascular outcomes","volume":"45","author":"Tsimikas","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacc.2026.07.015_bib18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/bmm.11.60","article-title":"Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events","volume":"5","author":"Taleb","year":"2011","journal-title":"Biomark Med"},{"issue":"8","key":"10.1016\/j.jacc.2026.07.015_bib19","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1016\/S0021-9258(18)61395-X","article-title":"Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products","volume":"262","author":"Steinbrecher","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2026.07.015_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2026.07.015_bib21","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.jacc.2026.07.015_bib22","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J Lipid Res"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726071408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726071408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:47:08Z","timestamp":1788292028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726071408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"alternative-id":["S0735109726071408"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.07.015","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}